# Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

> **NCT00245245** · PHASE2 · COMPLETED · sponsor: **Octagen Corporation** · enrollment: 12 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** recombinant porcine coagulation factor VIII (OBI-1)

## Key facts

- **NCT ID:** NCT00245245
- **Lead sponsor:** Octagen Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2007-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245245, "Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00245245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*